Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 2:19 AM
Ignite Modification Date:
2025-12-25 @ 2:19 AM
NCT ID:
NCT00262834
Eligibility Criteria:
Inclusion Criteria:
* No prior or concurrent hormonal therapy for breast cancer
* Histologically confirmed breast cancer, stage I-III disease, scheduled to undergo definitive surgery or other primary treatment (e.g., preoperative/neoadjuvant systemic treatment) for breast cancer
* ECOG 0-2 OR Karnofsky 60-100%
* Absolute neutrophil count ≥ 1,500/mm\^3
* Platelet count ≥ 100,000/mm\^3
* Bilirubin normal
* AST and ALT ≤ 2.5 times upper limit of normal
* PT ≤ 14 seconds
* Creatinine normal
* No symptomatic congestive heart failure
* No unstable angina pectoris
* No cardiac arrhythmia
* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective contraception
* No ongoing or active infection
* No psychiatric illness or social situation that would preclude study compliance
* No other uncontrolled intercurrent illness
* No history of allergic reaction attributed to compounds of similar chemical or biologic composition to vorinostat
* At least 30 days since prior hormone replacement therapy (e.g., estrogen and/or progestin)
* Concurrent vaginal hormone preparations (e.g., vagifem or estring) allowed
* No concurrent birth control pills
* No prior radiotherapy to the ipsilateral breast
* No prior or concurrent radiotherapy for breast cancer
* No prior or concurrent novel therapy for breast cancer
* At least 14 days since prior valproic acid or another histone deacetylase inhibitor
* No other concurrent investigational agents
* No concurrent combination antiretroviral therapy for HIV-positive patients
* No other concurrent therapy for this cancer
* WBC ≥ 3,000/mm\^3
Exclusion criteria:
* Patients must not be recieving any other investigational agents
* History of allergic reactions attributed to compounds of similar chemical or biologic composition to SAHA.
* Patients may not be taking valproic acid or another histone deacetylase inhibitor for at least 2 weeks prior to initiating SAHA.
* Women who are pregnant.
Healthy Volunteers:
False
Sex:
FEMALE
Minimum Age:
18 Years
Study:
NCT00262834
Study Brief:
Protocol Section:
NCT00262834